Introduction: All three of the genomes carrying the L452R/N501Y combination belonged to the A.27 lineage (clade 19B) and did not encode the D614G mutation that predominates most global infections today.
Introduction: In addition to the L452R + N501Y double mutant, a single genome was identified that carried a unique combination of E484K + N501T spike RBD mutations in a B.1 lineage genome (clade 20C) with D614G also present.
Additional Positive Electric Residues in the Crucial Spike Glycoprotein S Regions of the New SARS-CoV-2 Variants.
7Figure: The reference ""wild-type'"" virus B.1 was assumed (with no mutation D614G and other spike protein changes)."
Abstract: The most often observed were positive mutations, especially D614G and E484K, located in the region of S1/S2 junction, and in the receptor-binding domain (RBD), respectively.
Table: D614G
Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021.
Introduction: In contrast to AY.4.2, the B.1.617.2 strain with E484K had a significant reduction in virus neutralisation titres relative to D614G (4.0-fold) and all other Delta strains tested - B.1.617.2 (2.3-fold), AY.4 (2.3-fold), and AY.4.2 (1.7-fold) (p < 0.050 for all comparisons).
Introduction: Relative to the early pandemic strain (D614G), the AY.4.2 virus had a 2.3-fold reduction in median neutralisation titres (median titre: 199 vs 87; p < 0.001) (Figure 2).
Introduction: Relative to the early pandemic strain (D614G), the reduction in the AY.4.2 sub-lineage-associated virus neutralisation (2.3-fold) was not as pronounced as observed for the Beta variant (4.9-fold).
Introduction: The cohort (n = 30), vaccinated with two doses between 18 January and 15 May 2021, was select
Table: D614G
Estimating the transmission advantage of the D614G mutant strain of SARS-CoV-2, December 2019 to June 2020.
Abstract: By June 2021, all the emerging variants of concern carried the D614G mutation.
Abstract: IntroductionThe SARS-CoV-2 lineages carrying the amino acid change D614G have become the dominant variants in the global COVID-19 pandemic.
Abstract: The rapid spread of the G614 mutant suggests that it may have a transmission advantage over the D614 wildtype.AimOur objective was to estimate the transmission advantage of D614G by integrating phylogenetic and epidemiological analy
Conclusion: It is also important to acquire a thorough understanding of viral phenotypes, clinical and epidemiological characteristics of emerging SARS-CoV-2mutants such as D614G, such that surveillance and disease control measures could be adjusted dynamically to counter the evolving risks posed by dominant mutant clades.
A Multidimensional Cross-Sectional Analysis of Coronavirus Disease 2019 Seroprevalence Among a Police Officer Cohort: The PoliCOV-19 Study.
PMID: 34888394
2021
Open forum infectious diseases
Result: Antibodies from seropositive individuals demonstrated neutralization activity against D614G up to a dilution of 1:320 (Supplementary Figure D).
Result: Antibody titers of anti-NCP and anti-S antibodies correlated with the dilution titers showing the highest coefficient with dilution of D614G and the lowest coefficient with dilution of B.1.351 (Beta), with P<.001 in all pairs (Supplementary Table F).
Result: Similar to the overall results of neutralization assays, the neutralization capacity of serum against Alpha and Beta variants was poorer than it was against D614G, even with serum demonstrating both >37.5 U/mL COI anti-NCP antibodies and >65 U/mL anti-S antibodies.
Result: The dilutions were lower for B.1.1.7 (1:40 for anti-S antibodies and 1:80 for anti-NCP
Local occurrence and fast spread of B.1.1.7 lineage: A glimpse into Friuli Venezia Giulia.
Discussion: Indeed, mRNA based (Moderna, Pfizer-BioNTech), adenoviral based (Vaxzevria, Johnson&Johnson), and protein-based based (Novavax) vaccines are only able to induce a monoclonal response towards the Asp614Gly bearing SARS-CoV-2 Spike protein, therefore a steady acquisition of mutations that could eventually lead to an enhanced fitness should be carefully monitored.
Estimating the strength of selection for new SARS-CoV-2 variants.
Result: D614G shows a very similar pattern in the UK and Netherlands where the mutant was spreading in a way that is nearly indistinguishable from the wild-type strains for a period of several weeks in the early epidemic period.
Result: Because B.1.1.7 emerged after D614G became globally common, the absolute fitness of B.1.1.7 is likely greater.
Result: Estimates from our population-genetic model for this country do not disagree but have much larger uncertainty; across all countries, the estimate is close for D614G and lower for B.1.1.7.
Result: For D614G and B.1.1.7, these estimates are quite similar.
Result: In both cases, the mutant strain is much slower to rise, occurring over a period of months rather than weeks as was the case with D614
Table: D614G
Comparative MD Study of Inhibitory Activity of Opaganib and Adamantane-Isothiourea Derivatives toward COVID-19 Main Protease M(pro).
Conclusion: Also, molecular docking simulations are performed to predict the potential inhibitory potency of compounds 1-4 toward SARS-CoV-2 main protease Mpro and mutation of SARS-CoV-2 Spike (S) Protein D614G.
Conclusion: As regard molecular docking simulations with Spike (S) Protein D614G, the prominent inhibitory potency shows OPG, while examined adamantly- isothiourea derivatives possess similar inhibitory potential between each other.
Conclusion: The important thermodynamical parameters from docking simulations with D614G, Table S
Figure: Structure of Spike (S) protein (D614G) and its interactions with OPG and compounds 1-4.
Insights on the mutational landscape of the SARS-CoV-2 Omicron variant.
Result: Additionally, mutations such as D614G have previously been linked to increased infectivity via destabilization of the RBD-down spike protein conformation.
Loss of Neutralizing Antibody Response to mRNA Vaccination against SARS-CoV-2 Variants: Differing Kinetics and Strong Boosting by Breakthrough Infection.
Result: At the time of pre-vaccination sample collection D614G was the major circulating SARS-CoV-2 variant, while at the time off post-first dose and post-second dose D614G and Alpha were circulating, and at the six month time point Delta was the dominant strain.
Result: Following the first dose of mRNA vaccine, a strong nAb response was induced among HCWs compared to pre-vaccination across all variants (p < 0.001), which efficiently blocked virus entry; this was despite the huge variation in nAb titers of these individuals including against D614G (mean = 1140, 95% CI = 317-1963, range = 100-15954).
Result: In particular, following two vaccine doses, mRNA-1273 vaccinated HCWs exhibited 2.1-, 2.3-, 2.4-, and 1.3-fold higher nAb response compared to BNT162b2-vaccinated HCWs for D614G, Alpha, Beta, and Delta variants, respectively.
SARS_CoV_2 mutation literature information.
PMID: 
2021
Scientific reports
Browser Board
Co-occurred Entities
Filtrator
ViMRT